- InVivo Therapeutics (NASDAQ:NVIV) issues a PR saying its degradable polymer scaffold trial will "be ready to enroll patients in Q1 2014."
- The company also says it "will submit a filing containing proposed changes to its FDA-approved protocol and supporting documents within the next ten days."
- NVIV thinks the changes, if approved, would "accelerate the progress of [the] trial by eliminating barriers to enrollment and by expanding the number of sites from at least three to as many as six."
- Additionally, the company says it has temporarily suspended "most work" on hydrogel in order to focus on scaffold manufacturing. NVIV says it has "entered into discussions with a number of prospective corporate partners based on this new business model." (PR)